NASDAQ OMX

New Research Reveals Majority of Recruiters Ready for GDPR; Concerns Remain About Sourcing and Hiring Under New Guidelines

Dela

Data from Lever Examines How Organizations are Preparing for GDPR Compliance Specific to Recruiting and Hiring

 

SAN FRANCISCO, March 27, 2018 (GLOBE NEWSWIRE) -- While nearly three quarters of organizations feel confident in their ability to achieve General Data Protection Regulation (GDPR) compliance for their recruiting efforts by the May 25th deadline, most still harbor concerns about how the new regulations will impact their hiring process, according to new research from Lever, the recruiting software for more than 1,500 leading companies around the world. Lever surveyed 500 professionals across the EU and US directly involved in preparing their organizations for GDPR compliance for recruiting.

According to the survey results, 70 percent of respondents believe they will be prepared for GDPR compliant recruiting by May 25th, but preparation doesn't come overnight, or in a silo. Nearly a third of respondents say they are investing significant time and resources into becoming GDPR compliant and 73 percent are working with external or internal legal counsel to prepare.

Despite this high level of preparedness, 61 percent of respondents are concerned about the impact of GDPR on their recruiting and hiring processes, including how they source potential candidates. Respondents were also either 'very concerned' or 'extremely concerned' about adhering to specific requirements included in the regulations, such as:

  • Maintaining full records of recruiting processing activities (52 percent)
  • Determining when to get consent from candidates (50 percent)
  • Determining how long to store a candidate's personal data before deleting it or obtaining consent (47 percent)
  • Selecting software vendors who will enter into GDPR compliant contracts and meet data security requirements (46 percent)

Regardless of these concerns, the overwhelming majority (90 percent) of respondents who are already engaged in sourcing will continue to do so under GDPR.

"The GDPR deadline is quickly approaching, but few are discussing the potential impact these regulations will have on how organizations source, recruit and hire their talent," said Mike Walsh, Director of Product Marketing of Lever. "We hope this research serves as a catalyst within organizations to begin discussing in detail how they will move forward with sourcing candidates under GDPR and the lengths they will go to protect candidate data. At Lever, we have spent significant time working on these issues on behalf of our clients and hope to continue to serve as a resource for recruiters worldwide."

Lever's research also revealed some organizations are unsure how to adhere to regulations related to candidate data. According to the GDPR, organizations must identify their own "lawful basis" for processing personal candidate data. For recruiting, the most common lawful bases are consent and legitimate interest, but it can be a grey area for many recruiters.

For example, respondents are split regarding when to collect consent from candidates. Only 40 percent of respondents will collect consent to contact for jobs they did not apply to, 37 percent will collect consent in order to email candidates they source and 25.5 percent will collect consent when they plan to keep data from candidates who were in their ATS before May 25th, 2018.

Another grey area the survey addressed was determining how long to store candidate data. While GDPR requires companies to only keep personal data for "no longer than is necessary for the purposes for which the personal data are processed," the data showed great variation in how organizations are interpreting this obligation. Some companies will delete candidate data as soon as the job they were tied to closes (23 percent), while others plan to retain candidate data for a year or more (23 percent).

The full research report can be downloaded at this link.

Methodology
From March 2 - 8, 2018, Lever surveyed 500 professionals across the EU and US who are directly involved in preparing their organizations for GDPR compliance for recruiting.

About Lever
Built from the conviction that recruiting is the responsibility of everyone at the company, Lever's applicant tracking and sourcing technology draws the entire team together to source, nurture, interview, and hire top talent through effortless collaboration. Lever has been intentionally designed with integrated ATS and CRM functionality, and features a modern interface that helps employers develop stronger candidate relationships in fewer clicks. 

Lever was founded in 2012 in San Francisco. The company has raised more than $73 million in funding from Adams Street Partners, Scale Venture Partners, Matrix Partners, Y Combinator, Redpoint Ventures, and Correlation Ventures among others. Lever supports the hiring needs of over 1,500 companies around the globe including the teams at Netflix, Hot Topic, KPMG New Zealand, and Cirque du Soleil. With an overall gender ratio of 50:50, Lever is also fiercely committed to building a team culture that celebrates diversity and inclusion. For more information, visit https://www.lever.co.

MEDIA CONTACT:
Ashley Cohen
Traeger Communications
acohen@traegercommunications.com
303-522-0783




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lever, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16Pressmeddelande

London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h

SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00Pressmeddelande

MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors24.5.2018 13:00Pressmeddelande

- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal grow

PRA Named International Clinical Research Company of the Year24.5.2018 10:00Pressmeddelande

RALEIGH, N.C., May 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. This is the fifth year in a row that PRA has received this award. "This award celebrates excellence in the clinical research industry and we are honored to once again be recognized by our peers," said Colin Shannon, President and Chief Executive Officer. "This award is possible thanks to the incredibly talented PRA team members we have working around the world who are deeply committed to their work in bringing new and life-saving therapies to the patients who need them." PRA also swept the Clinical Research Associate and Clinical Trial Administrator categories capturing a total of 11 awards. These awards follow PRA's recognition earlier this month in the PharmaTimes Americas competition where PRA also received 11 awards, including Company of the Year. The PharmaTimes, International Cli

Immunicum AB: Inbjudan till investerarträff24.5.2018 08:00Pressmeddelande

Pressmeddelande 24 maj 2018 Immunicum AB: Inbjudan till investerarträff Immunicum AB (publ; IMMU.ST) meddelade i dag att bolaget kommer att anordna en investerarträff i Kalmar den 13 juni kl. 18:00 CEST. Carlos de Sousa, Immunicums VD, kommer att hålla en presentation av det dagsaktuella läget, och han och övriga i ledningen kommer vara tillgängliga för att svara på frågor. Kalmar Datum: Onsdag 13 juni 2018 Tid: 18:00 - 20:00 CEST Plats: Kalmar Slott, Kungsgatan 1, 392 33 Kalmar För att delta på träffen, skicka ett mejl till events@immunicum.com med ditt fullständiga namn. För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: ir@immunicum.com Media Relations Gretchen Schweitzer och Joanne Tudorica Trophic Communications Telefon: +49 172 861 8540 E-post: ir@immunicum.com Om Immunicum AB (publ) Immunicum etablerar ett unikt angreppssätt inom im

Immunicum AB: Invitation to Investor Event24.5.2018 08:00Pressmeddelande

Press Release 24 May 2018 Immunicum AB: Invitation to Investor Event Immunicum AB (publ; IMMU.ST) announced today that the Company will host an investor event in Kalmar on June 13 starting at 18:00 CEST. Carlos de Sousa, CEO of Immunicum, will give the current corporate presentation and he and other members of the Immunicum leadership team will be available for a question and answer session. Kalmar Date: Wednesday, June 13, 2018 Time: 18:00 - 20:00 CEST Location: Kalmar Slott, Kungsgatan 1, 392 33 Kalmar To register to attend the event, please send an email to events@immunicum.com with your full name. For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer and Joanne Tudorica Trophic Communications Telephone: +49 172 861 8540 E-mail: ir@immunicum.com About Immunicum AB (publ) Immunicum is establis

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum